WO2010013969A3 - Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci - Google Patents

Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci Download PDF

Info

Publication number
WO2010013969A3
WO2010013969A3 PCT/KR2009/004277 KR2009004277W WO2010013969A3 WO 2010013969 A3 WO2010013969 A3 WO 2010013969A3 KR 2009004277 W KR2009004277 W KR 2009004277W WO 2010013969 A3 WO2010013969 A3 WO 2010013969A3
Authority
WO
WIPO (PCT)
Prior art keywords
salts
salt
benzamidine
alendronic acid
preventing
Prior art date
Application number
PCT/KR2009/004277
Other languages
English (en)
Other versions
WO2010013969A2 (fr
Inventor
Jin Soo Lee
Yun Ha Hwang
Jei Man Ryu
Jae Hoon Park
Duk Kyun Chung
Original Assignee
Dong Wha Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharmaceutical Co., Ltd. filed Critical Dong Wha Pharmaceutical Co., Ltd.
Priority to EP09803174A priority Critical patent/EP2307015A4/fr
Priority to CA2732863A priority patent/CA2732863A1/fr
Priority to JP2011521043A priority patent/JP2011529875A/ja
Priority to CN2009801335635A priority patent/CN102149380B/zh
Publication of WO2010013969A2 publication Critical patent/WO2010013969A2/fr
Publication of WO2010013969A3 publication Critical patent/WO2010013969A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour prévenir et traiter l'ostéoporose, qui comprend du N-hydroxy-4-{5-[4-(5-isopropyl-2-méthyl-1,3-thiazol-4-yl)phénoxy]pentoxy}benzamidine, du 4-{5-[4-(5-isopropyl-2-méthyl-1,3-thiazol-4-yl)phénoxy]pentoxy}benzamidine, ou des sels de ceux-ci, et de l'acide alendronique ou un sel de celui-ci. En tant que composition prophylactique ou thérapeutique pour l'ostéoporose, un traitement combiné à base de N-hydroxy-4-{5-[4-(5-isopropyl-2-méthyl-1,3-thiazol-4-yl)phénoxy]pentoxy}benzamidine, de 4-{5-[4-(5-isopropyl-2-méthyl-1,3-thiazol-4-yl)phénoxy]pentoxy}-benzamidine, ou de sels de ceux-ci et d'acide alendronique ou d'un sel de celui-ci permet d'assurer un excellent effet inhibiteur sur la différenciation des ostéoclastes, par comparaison avec chaque traitement individuel, ce qui s'avère être utile pour la prévention ou le traitement de l'ostéoporose.
PCT/KR2009/004277 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci WO2010013969A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP09803174A EP2307015A4 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
CA2732863A CA2732863A1 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prevenir ou traiter l'osteoporose a base de derives de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
JP2011521043A JP2011529875A (ja) 2008-08-01 2009-07-31 ベンズアミジン誘導体またはその塩、およびアレンドロン酸またはその塩を含む骨粗鬆症の予防または治療用薬学的組成物
CN2009801335635A CN102149380B (zh) 2008-08-01 2009-07-31 包含苄脒衍生物或其盐和阿仑膦酸或其盐、用于预防或治疗骨质疏松症的药物组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0075792 2008-08-01
KR20080075792 2008-08-01

Publications (2)

Publication Number Publication Date
WO2010013969A2 WO2010013969A2 (fr) 2010-02-04
WO2010013969A3 true WO2010013969A3 (fr) 2010-05-27

Family

ID=41610865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004277 WO2010013969A2 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Country Status (6)

Country Link
EP (1) EP2307015A4 (fr)
JP (1) JP2011529875A (fr)
KR (1) KR20100014173A (fr)
CN (1) CN102149380B (fr)
CA (1) CA2732863A1 (fr)
WO (1) WO2010013969A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
KR19980071076A (ko) * 1997-02-04 1998-10-26 서홍석 3-아미노-1,2-벤조이소옥사졸 유도체, 이의 제조방법 및 용도
WO2003007947A1 (fr) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Utilisation de derives de 4-[(4-thiazolyl)phenoxy]alcoxy-benzamidine dans le traitement de l'osteoporose

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144806A (zh) * 1996-07-25 1997-03-12 南京药物研究所 氨基二膦酸类骨吸收抑制剂及其钠盐的制备方法
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
JP2003292453A (ja) * 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
JPWO2005002590A1 (ja) * 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
JP2007502300A (ja) * 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
US7410977B2 (en) * 2004-04-28 2008-08-12 Merck & Co., Inc. Fluorinated 4-azasteroids as androgen receptor modulators
AU2005260327B2 (en) * 2004-07-05 2009-10-01 Dong Wha Pharmaceutical Co., Ltd. Pharmaceutical composition for the treatment of bone fracture
JP2009017222A (ja) * 2007-07-04 2009-01-22 Panasonic Corp 色調整装置、色調整方法および色調整装置の集積回路
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
KR19980071076A (ko) * 1997-02-04 1998-10-26 서홍석 3-아미노-1,2-벤조이소옥사졸 유도체, 이의 제조방법 및 용도
WO2003007947A1 (fr) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Utilisation de derives de 4-[(4-thiazolyl)phenoxy]alcoxy-benzamidine dans le traitement de l'osteoporose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENNIS M. BLACK ET AL.: "The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 13, 25 September 2003 (2003-09-25), pages 1207 - 1215, XP009045315 *
See also references of EP2307015A4 *

Also Published As

Publication number Publication date
CN102149380B (zh) 2012-12-05
CN102149380A (zh) 2011-08-10
WO2010013969A2 (fr) 2010-02-04
KR20100014173A (ko) 2010-02-10
EP2307015A2 (fr) 2011-04-13
CA2732863A1 (fr) 2010-02-04
JP2011529875A (ja) 2011-12-15
EP2307015A4 (fr) 2012-05-16

Similar Documents

Publication Publication Date Title
WO2010032875A3 (fr) Composés de carboxamide hétérocycliques
WO2008136428A1 (fr) Composé hétérocyclique à cinq chaînons à teneur en azote
WO2010057101A3 (fr) Composés utiles en tant qu’inhibiteurs de vih
WO2010021680A3 (fr) Inhibiteurs de la bêta-sécrétase
WO2009080705A3 (fr) Composés organiques
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
GEP20125650B (en) Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
WO2012009715A3 (fr) Nouveaux dérivés de la cyclosporine destinés à traiter et à prévenir une infection virale
NZ595674A (en) Imidazo[2,1-b][1,3,4]thiadiazole derivatives
WO2011159129A3 (fr) Nouveaux dérivés de rhodanine, procédé pour les préparer et composition pharmaceutique pour la prévention ou le traitement du sida contenant les dérivés de rhodanine comme principes actifs
MY195675A (en) A Group of Compounds used for the Treatment or Prevention of Hyperuricemia or Gout
NZ602125A (en) Uses of dgat1 inhibitors
WO2011159137A3 (fr) Nouvelle thio-urée ou nouveau dérivé d'urée, procédé permettant leur préparation, et composition pharmaceutique destinée à prévenir ou à traiter le sida, les contenant en tant que principe actif
NZ598750A (en) Therapeutic agent for mood disorders
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
WO2009030952A3 (fr) Composés hétérocycliques et leurs procédés d'utilisation
MY187899A (en) (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
WO2009051223A1 (fr) Composition pharmaceutique pour le traitement de la cataracte
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2008000421A3 (fr) Composés organiques
WO2009145591A3 (fr) Composés de phényl-pipérazine, composition pharmaceutique les comprenant, et utilisation associée
EP2865668A3 (fr) Inhibiteurs et procédés d'inhibition de pathogènes bactériens et viraux
WO2014149139A3 (fr) Halogénopyrazoles en tant qu'inhibiteurs de la thrombine
WO2010013969A3 (fr) Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
WO2010013975A3 (fr) Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980133563.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803174

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732863

Country of ref document: CA

Ref document number: 2011521043

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009803174

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE